Table 2.
Association analyses between adverse effects and categorizing exposure levels
| Quartiles | n | Myelosuppression (Grade) | Edema Limbs (Grade) | Rash (Grade) | Myalgia (Grade) | Periocular Edema (Grade) | Conjunctival Hemorrhage (Grade) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2+ | P a | 0 | 1 | 2+ | P a | 0 | 1 | 2+ | P a | 0 | 1+ | P a | 0 | 1+ | P a | 0 | 1 | 2+ | P a | ||
| Imatinib | |||||||||||||||||||||||
| Q1 | 30 | 21 | 5 | 4 | <0.001 | 25 | 2 | 3 | 0.674 | 27 | 3 | 0 | 0.560 | 22 | 8 | 0.891 | 13 | 17 | 0.266 | 28 | 2 | 0 | 0.779 |
| Q2 | 31 | 22 | 7 | 2 | 0.125 | 25 | 3 | 3 | 0.762 | 24 | 5 | 2 | 0.244 | 25 | 6 | 7 | 24 | 27 | 4 | 0 | 0.870 | ||
| Q3 | 31 | 11 | 13 | 7 | 23 | 5 | 3 | 25 | 6 | 0 | 24 | 7 | 8 | 23 | 26 | 4 | 1 | ||||||
| Q4 | 30 | 9 | 13 | 8 | 26 | 3 | 1 | 26 | 4 | 0 | 22 | 8 | 7 | 23 | 27 | 2 | 1 | ||||||
| NDI | |||||||||||||||||||||||
| Q1 | 32 | 20 | 8 | 4 | 0.006 | 27 | 1 | 2 | 0.073 | 26 | 4 | 0 | 0.852 | 20 | 10 | 0.331 | 12 | 18 | 0.387 | 26 | 4 | 0 | 0.907 |
| Q2 | 31 | 23 | 6 | 2 | 0.138 | 26 | 4 | 1 | 0.363 | 25 | 4 | 2 | 0.244 | 24 | 7 | 7 | 24 | 28 | 3 | 0 | 0.870 | ||
| Q3 | 37 | 12 | 17 | 8 | 20 | 6 | 5 | 25 | 6 | 0 | 23 | 8 | 7 | 24 | 28 | 2 | 1 | ||||||
| Q4 | 35 | 12 | 16 | 7 | 26 | 2 | 2 | 26 | 4 | 0 | 26 | 4 | 9 | 21 | 26 | 3 | 1 | ||||||
a
P value of row 1 was grade 0 versus 1 + ; P value of row 2 was grade 0&1 versus 2+.